23. The molecule of claim **21**, wherein the ligand comprises an aptamer.

24. The molecule of claim **22**, wherein the aptamer binds to EGFR, PDGFR, folate receptor, or a combination thereof.

25. The molecule of claim **1**, wherein the targeting module comprises a folate.

26. (canceled)

27. The molecule of claim **2**, wherein the bioactive agent comprises a drug, a therapeutic agent, a fluorescent dye, a chemical, an siRNA, an miRNA, an anti-miRNA, a ribozyme RNA, an antisense RNA or a combination thereof.

28. (canceled)

29. The molecule of claim **2**, wherein the bioactive agent is directed to a brain tumor marker.

30. (canceled)

31. (canceled)

32. The molecule of claim **27**, wherein the microRNA sequence is at least 6 nucleotide in length.

33. The molecule of claim **27**, wherein the bioactive agent is an anti-miRNA molecule for a miRNA comprising miR-9, miR-10b, miR-21, miR-17, or miR-26.

34. The molecule of claim **27**, wherein the bioactive agent is a miRNA molecule for a miRNA comprising let-7a, miR-10b, miR-25, miR-34a, miR-124, miR-145, or miR-18 lb.

35. The molecule of claim **33**, wherein the anti-miRNA comprises an anti-miRNA locked nucleic acid (LNA) molecule.

36. The molecule of claim **35**, wherein the anti-miRNA LNA molecule comprises sequence 5'-GATAAGCT-3', 5'-AGCACTTT-3', or 5'-ATTTGCAC-3'.

37. (canceled)

38. (canceled)

39. (canceled)

40. The molecule of claim **27**, wherein the mRNA molecule encodes a protein comprising VEGF, EGFR, POK, AKT, AGT, RAF, RAS, MAPK, ERK, MGMT, MMP-2, MMP-9, PDGF, PDGFR, IGF-1, HGF, mTOR, Cox-2 or TGFβ1.

41. The molecule of claim **27**, wherein the siRNA binds to a mRNA molecule that encodes RAS, cMET, HER2, MDM2, PIK3CA, AKT, CDK4, or a combination thereof.

42. A nucleic acid composition, comprising a therapeutically effective amount of the RNA nano structure of claim **1**.

43. The composition of claim **42**, further comprising a pharmaceutically acceptable carrier.

44. The artificial RNA nanostructure of claim **1**, wherein the RNA nanostructure comprises a nanoparticle delivery system.

45. The nanoparticle delivery system of claim **44**, further comprising a pharmaceutically acceptable carrier.

46. A method of treating a brain tumor in a subject having or at risk of developing a brain tumor, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a molecule of claim **1**.

47. (canceled)

48. (canceled)

49. (canceled)

50. (canceled)

51. The method of claim **46**, wherein the brain tumor is glioblastoma.

* * * * *